FindTrial
Sign In

Effect of N-Acetyl cystine on endothelial dysfunction,oxidative stress,inflammation in dialysis patients.

â??Effect of N-Acetyl Cystine on endothelial dysfunction, biomarkers of oxidative stress and inflammation in subjects undergoing high and low flux hemodialysis at a tertiary care hospital

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012586
Enrollment
40
Registered
2018-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- CHRONIC KIDNEY DISEASE PATIENTS ON HEMODIALYSIS

Interventions

Intervention1: N-ACETYL CYSTEINE: N-ACETYL CYSTEINE 600mg TWICE daily,oral dose per 12weeks Control Intervention1: IDENTICAL PLACEBO: PLACEBO twice daily,oral dose,for 12weeks

Sponsors

GSrinivas
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender (male/female) aged 18 -70 years. 2. Subjects undergoing hemodialysis 2 or 3 times a week for more than 3 months. 3. Hemodialysis patients naive to NAC. 4. Body mass index between 25 to 35 kg/m2. 5. Stable dose of concomitant medication for diabetes mellitus, hypertension for past 8 weeks. 6. All patients willing to give consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients taking vitamins C or E for the past 1 month. 2. Patients with chronic inflammatory disease. 3. Patients having a medical history of alcohol abuse. 4. Patients with malignancy. 5. Patients with pre-existing hematological disorders. 6. Post renal transplantation patients. 7. Patients with hypersensitivity to NAC.

Design outcomes

Primary

MeasureTime frame
1. To observe the effect of N-acetylcysteine (600 mg twice a day) on biomarkers of oxidative stress and inflammation on patients with high flux and low flux HD. 2. To observe the effect of N-acetylcysteine (600 mg twice a day) on endothelial function in patients undergoing high and low flux hemodialysis. Timepoint: 0,4,12weeks—

Secondary

MeasureTime frame
Tolerability of NAC.Timepoint: 0,4,12weeks—

Countries

India

Contacts

Public ContactGSrinivas

Nizamâ??s Institute of Medical Sciences

ushapingali@yahoo.com9640972888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026